-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MER-3101 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MER-3101 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MER-3101 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MER-3001 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MER-3001 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MER-3001 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVCoV-2 in Middle East Respiratory Syndrome (MERS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVCoV-2 in Middle East Respiratory Syndrome (MERS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVCoV-2 in Middle East Respiratory Syndrome (MERS) Drug Details:...
-
Product Insights
Tyrosine Protein Kinase Mer – Drugs In Development, 2023
Global Markets Direct’s Tyrosine Protein Kinase Mer provides in depth analysis on Tyrosine Protein Kinase Mer targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Courseulles sur Mer Offshore
Courseulles sur Mer Offshore is an offshore wind project located in English Channel, France. The project is owned by Canada Pension Plan Investment Board; EDF Renewables SA; Enbridge Inc; WPD Offshore France SAS and is developed by Eolien Maritime France; WPD Offshore France SAS. The project is currently under construction. Empower your strategies with our Courseulles sur Mer Offshore report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report...
-
Product Insights
Neoen Mer Solar PV Park
Neoen Mer Solar PV Park is a solar PV project located in Centre-Val de Loire, France. The project is owned and developed by Neoen SA. The project came online in 2021. Empower your strategies with our Neoen Mer Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
Cent Planches Mer Solar PV Park
Cent Planches Mer Solar PV Park is a solar PV project located in Centre-Val de Loire, France. The project is owned and developed by Neoen SA. The project came online in 2021. Empower your strategies with our Cent Planches Mer Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....
-
Product Insights
Centrale Photovoltaique de Mer Solar PV Park
Centrale Photovoltaique de Mer Solar PV Park is a solar PV project located in Centre-Val de Loire, France. The project is owned by Neoen SA and was developed by Centrale Photovoltaique de Mer. The project came online in 2021. Empower your strategies with our Centrale Photovoltaique de Mer Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-03 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-03 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-03 in Idiopathic Pulmonary Fibrosis Drug Details: LTI-03 is under development...